• Publications
  • Influence
Are Ambient Ultrafine, Accumulation Mode, and Fine Particles Associated with Adverse Cardiac Responses in Patients Undergoing Cardiac Rehabilitation?
Background: Mechanisms underlying previously reported air pollution and cardiovascular (CV) morbidity associations remain poorly understood. Objectives: We examined associations between markers ofExpand
  • 85
  • 6
  • PDF
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
IMPORTANCE Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine neurons, and was safeExpand
  • 189
  • 4
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
IMPORTANCE Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives and may therefore lead to stable systemic exposureExpand
  • 106
  • 4
Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study
To test the association between impaired olfaction and other prodromal features of PD in the Parkinson At‐Risk Syndrome Study. The onset of olfactory dysfunction in PD typically precedes motorExpand
  • 149
  • 3
Imaging prodromal Parkinson disease
Objectives: The purpose of this study is to evaluate the relative risk of abnormal dopamine transporter (DAT) imaging for subjects with and without hyposmia and the feasibility of acquiring a large,Expand
  • 83
  • 2
Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments
The Movement Disorder Society (MDS) commissioned a revision of the UPDRS with the goals of improving instructions and definitions, more accurately evaluating milder features, and assessingExpand
  • 32
  • 2
Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.
There are no cures for neurodegenerative diseases and this is partially due to the difficulty of monitoring pathogenic molecules in patients during life. The Parkinson's disease gene α-synucleinExpand
  • 37
  • 1
  • PDF
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
IMPORTANCE Identifying measures that are associated with the cytosine-adenine-guanine (CAG) expansion in individuals before diagnosis of Huntington disease (HD) has implications for designingExpand
  • 34
  • 1
  • PDF
Cardiovascular effects of ozone in healthy subjects with and without deletion of glutathione-S-transferase M1
Abstract Context: Exposure to ozone has acute respiratory effects, but few human clinical studies have evaluated cardiovascular effects. Objective: We hypothesized that ozone exposure altersExpand
  • 23
  • 1
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slowExpand
  • 15
  • 1